DelveInsight's "VITRAKVI Market Size, Forecast, and Market Insight Report" highlights the details around VITRAKVI, a TRK, ...

VITRAKVI has strong market potential as a first-in-class TRK inhibitor for patients with NTRK gene fusion-positive cancers, regardless of tumor type. The growing adoption of precision oncology ...

Want to learn about a clinical trial targeting patients who have tumours with ALK or ROS1 gene alterations?' reads a recent tweet from @NovartisCancrUS, Novartis' Twitter channel dedicated to its ...

The EU drugs regulator cleared Vitrakvi (larotrectinib) for the treatment of patients with solid tumours that have an NTRK gene fusion ... a second indication – ROS1-positive metastatic non ...

However, sometimes the gene is erroneously turned on by fusing with other genes. This errant process, called ALK rearrangement, can lead to unchecked cell growth and cancer development. The ROS1 gene ...

Dec. 10, 2024 — In a single IV injection, a gene therapy targeting cBIN1 can reverse the effects of heart failure and restore heart function in a large animal model. The therapy increases the ...

We then conducted a WGCNA [weighted gene co-expression network analysis], which divided the gene into six modules. We focused on those modules that differed among clusters 1, 2, and 4. Green ...

A gene regulatory network is a set of genes, or parts of genes, that interact with each other to control a specific cell function. Gene regulatory networks are important in development ...

Panelists discuss treatment decision-making for metastatic non–-small cell lung cancer (NSCLC) with a ROS1 alteration, ...

During a Community Case Forum event in partnership with the Texas Society of Clinical Oncology, Natalie Vokes, MD, discussed trials of targeted agents for EGFR-mutant lung cancer. Peers & Perspectives ...